LGALS9 and neoplasm: Complementary to molecular inhibition, Ren et al. recently demonstrated that a tumor-targeted nanodrug (FSGG/siGal-9) combined with photothermal therapy enhances Gal-9 blockade efficacy, promoting cytotoxic T-cell recruitment and melanoma regression in vivo.